MB7 / Mustbio - LARVOL DELTA

A novel αPD-1/αVEGF/IL-21v tri-specific fusion protein exhibits potent antitumor efficacy beyond αPD-1/αVEGF bispecific therapy (AACR 2026) - "The αPD-1/αVEGF/IL-21v exhibited PD-1/PD-L1 blocking activity comparable to pembrolizumab and VEGF/VEGFR blockade similar to bevacizumab...This long-lasting efficacy was associated with an increased intratumoral CD8+T/Treg ratio and expansion of memory T cell populations within tumors rather than in peripheral blood. In conclusion, αPD-1/αVEGF/IL-21v is a novel TME-selective tri-specific fusion protein that enhances TIL recruitment and amplifies effector/memory T cell populations, offering therapeutic potential beyond αPD-1 or αPD-1/αVEGF therapy."

Bispecific • Clinical • Trispecific • Oncology • CD8 • GZMB • IFNG • IL21 • STAT3